# Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
Canonical URL: https://biopharmsignal.com/news/BPTH/bio-path-holdings-to-host-corporate-update-conference-call-on-may-29-2025-7d0815d0
Ticker: BPTH
Company: Bio-Path Holdings
Source: Bio-Path Holdings
Published: 2025-05-22 20:30 EST
## Summary

Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense...

## Article Body
Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview.

To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com . An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize ® , a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. BP1001-A is also being evaluated as a treatment for obesity and related metabolic diseases in Type 2 diabetes patients. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at http://www.biopathholdings.com .

Contact Information:

Investors

Will O’Connor Stern Investor Relations 212-362-1200 will@sternir.com

Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
## Recent Company News
- 2025-06-09 11:00 EST — [Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum](https://biopharmsignal.com/news/BPTH/bio-path-holdings-to-present-at-life-sciences-virtual-investor-forum-6c80073e) — Source: Bio-Path Holdings
- 2025-06-03 11:00 EST — [Bio-Path Holdings Provides Clinical and Operational Update](https://biopharmsignal.com/news/BPTH/bio-path-holdings-provides-clinical-and-operational-update-945f6be3) — Source: Bio-Path Holdings
- 2025-05-22 20:30 EST — [Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025](https://biopharmsignal.com/news/BPTH/bio-path-holdings-to-host-corporate-update-conference-call-on-may-29-2025-7d0815d0) — Source: Bio-Path Holdings
- 2025-05-01 11:00 EST — [Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients](https://biopharmsignal.com/news/BPTH/bio-path-holdings-achieves-third-pre-clinical-milestone-confirming-potential-of--a70a6183) — Source: Bio-Path Holdings
- 2025-03-28 11:00 EST — [Bio-Path Holdings Reports Full Year 2024 Financial Results](https://biopharmsignal.com/news/BPTH/bio-path-holdings-reports-full-year-2024-financial-results-d19bcd3b) — Source: Bio-Path Holdings
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)